TA-NIC
Description
Name: TA-NIC
Type: biotech
Groups: investigational
Indication: Investigated for use/treatment in tobacco dependence.
Accession Number: DB05445 ( DB05445)
Description: TA-NIC is a novel and proprietary vaccine in development as an aid to quitting smoking in motivated patients. TA-NIC is an immunotherapeutic vaccine similar in concept to TA-CD, designed to raise anti-nicotine antibodies. The antibodies bind to nicotine molecules in the patient's blood stream, reducing the rate and quantity of nicotine entry into the brain and thus reducing the positive reinforcement and addiction associated with nicotine and cigarette smoking. It is expected that the reduction of the positive reinforcement will in turn reduce the desire to smoke or use other tobacco products.
Structure:
Prescription Products: Not Available
Generic Prescription Products: Not Available
Over the Counter Products: Not Available
International Brands
Brand Names
Brand Mixtures
Categories
Type: biotech
Groups: investigational
Indication: Investigated for use/treatment in tobacco dependence.
Accession Number: DB05445 ( DB05445)
Description: TA-NIC is a novel and proprietary vaccine in development as an aid to quitting smoking in motivated patients. TA-NIC is an immunotherapeutic vaccine similar in concept to TA-CD, designed to raise anti-nicotine antibodies. The antibodies bind to nicotine molecules in the patient's blood stream, reducing the rate and quantity of nicotine entry into the brain and thus reducing the positive reinforcement and addiction associated with nicotine and cigarette smoking. It is expected that the reduction of the positive reinforcement will in turn reduce the desire to smoke or use other tobacco products.
Structure:
Prescription Products: Not Available
Generic Prescription Products: Not Available
Over the Counter Products: Not Available
International Brands
- No Brands
Brand Names
- No Brands
Brand Mixtures
| Brand Name | Ingredients |
|---|
| Brand Name | Ingredients |
|---|
Categories
- No Category
Pharmacology
Indication: Investigated for use/treatment in tobacco dependence.
Pharmacodynamics: Not Available
Mechanism of action: Reduces nicotine entry into the brain and thus the positive reinforcement associated with smoking.
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: TA-NIC consists of nicotine conjugated to the carrier protein rCTB and an aluminium adjuvant.
Metabolism: Not Available
Route of elimination: Not Available
Half life: Not Available
Clearance: Not Available
Toxicity: Appears to be well-tolerated.
Affected organisms
SNP Mediated Adverse Drug Reactions
Pharmacodynamics: Not Available
Mechanism of action: Reduces nicotine entry into the brain and thus the positive reinforcement associated with smoking.
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: TA-NIC consists of nicotine conjugated to the carrier protein rCTB and an aluminium adjuvant.
Metabolism: Not Available
Route of elimination: Not Available
Half life: Not Available
Clearance: Not Available
Toxicity: Appears to be well-tolerated.
Affected organisms
- Not Available
SNP Mediated Adverse Drug Reactions
- Not Available
Pharmacoeconomics
Manufacturers:
Packagers:
Dosage forms
Prices
Patents
- Not Available
Packagers:
- Not Available
Dosage forms
| Form | Route | Strength |
|---|
| Form | Route | Strength |
|---|
Prices
| Unit description | Cost | Unit |
|---|
| Unit description | Cost | Unit |
|---|
Patents
| Country | Patent Number | Approved | Expires (estimated) |
|---|
Interactions
Drug Interactions
Food Interactions:
| Drug | Interaction |
|---|
| Drug | Interaction |
|---|
Food Interactions:
- Not Available
Taxonomy
Kingdom: Organic Compounds
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
substituent:
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
- Not Available
substituent:
- Not Available
References
Synthesis Reference: Not Available
General Reference: # Goniewicz ML, Koszowski B, Czogala J, Zymelka A: [New prospects of nicotine dependence treatment--vaccines] Przegl Lek. 2006;63(10):1114-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17288232 # Cerny T: Anti-nicotine vaccination: where are we? Recent Results Cancer Res. 2005;166:167-75. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15648190 # Trial watch: Xenova's TA-NIC vaccine shows promise. Expert Rev Vaccines. 2004 Aug;3(4):386. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15270640 # Hagenbuch B, Meier PJ: Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter. J Clin Invest. 1994 Mar;93(3):1326-31. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8132774
External Links:
ATC Codes:
AHFS Codes:
MSDS: Download
General Reference: # Goniewicz ML, Koszowski B, Czogala J, Zymelka A: [New prospects of nicotine dependence treatment--vaccines] Przegl Lek. 2006;63(10):1114-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17288232 # Cerny T: Anti-nicotine vaccination: where are we? Recent Results Cancer Res. 2005;166:167-75. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15648190 # Trial watch: Xenova's TA-NIC vaccine shows promise. Expert Rev Vaccines. 2004 Aug;3(4):386. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15270640 # Hagenbuch B, Meier PJ: Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter. J Clin Invest. 1994 Mar;93(3):1326-31. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8132774
External Links:
| Resource | Link |
|---|
| Resource | Link |
|---|
ATC Codes:
- Not Available
AHFS Codes:
- Not Available
MSDS: Download